Eli Lilly & Co. vs. Spyre Therapeutics, Inc. Common Stock
Eli Lilly & Co. and Spyre Therapeutics, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| LLY | SYRE | |
|---|---|---|
| Market Cap | $1.06 trillion | $8.25 billion |
| Revenue (TTM) | $79.67 billion | — |
| Net Income (TTM) | $26.71 billion | — |
LLY leads on 1 of 1 size & scale factors.
Valuation
| LLY | SYRE | |
|---|---|---|
| P/E Ratio | 39.93 | — |
| Price / Book | 31.29 | — |
| Price / Sales | 13.31 | — |
LLY and SYRE split the valuation factors evenly.
Profitability
| LLY | SYRE | |
|---|---|---|
| Net Margin | 33.53% | — |
| Return on Equity | 78.84% | — |
LLY and SYRE split the profitability factors evenly.
Dividend
| LLY | SYRE | |
|---|---|---|
| Dividend Yield | 0.58% | — |
| Payout Ratio | 23.23 | — |
LLY and SYRE split the dividend factors evenly.
Risk & Sentiment
| LLY | SYRE | |
|---|---|---|
| Short Interest | 1.29% | 0.23% |
SYRE leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, SYRE overview, SYRE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.